scispace - formally typeset
Y

Yoshitaka Fujii

Researcher at Nagoya City University

Publications -  306
Citations -  22300

Yoshitaka Fujii is an academic researcher from Nagoya City University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 59, co-authored 304 publications receiving 21040 citations.

Papers
More filters
Journal ArticleDOI

Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer.

TL;DR: Using the LightCycler RT-PCR assay, the determination of PPARgamma mRNA levels might provide a potential marker for treatment of lung cancer by PPARGamma agonist, however, further studies and a longer follow up are needed to confirm the impact of PPargamma in the biological behavior of the tumor.
Journal ArticleDOI

Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer.

TL;DR: The mRNA expression level of PPAR gamma may be a marker of prognosis after operation in esophageal cancer patients and this work examined the correlation between the expression of PPar gamma mRNA with prognosis of esophagesia cancer patients.
Journal ArticleDOI

Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers.

TL;DR: It is found that the BUB gene family members including BUB1, BUBR1 and BUB3 are not frequent targets for mitotic checkpoint defects in lung cancers, if present at all.
Journal ArticleDOI

A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma

TL;DR: Adenocarcinomas with BAC components in male non-smokers seem to predict the presence of EGFR mutation, and patient prognosis is predicted to be better than that of patients with adenOCarcinoma with Bac components with wild-type EGFR gene.
Journal ArticleDOI

p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma.

TL;DR: The data suggest that, unlike other more common cancers, alteration of the p53 gene may not play a significant role in the tumorigenesis of thymoma, however, inactivation of p16INK4A and RB may play a role inThe progression ofThymoma and thymic carcinoma.